Figure S4 from SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
Abstract
Figure S4 showes the cell killing potency of the indicated mAb, ADCs, and payloads in cell lines of multiple cancer types.
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Protein Degradation and Inhibitors
Cancer Immunotherapy and Biomarkers
Publication details
- Publication date
- 4 February 2026